FDA
FDA moves to block bulk compounding of popular GLP-1 drugs
Clinical Takeaway: Clinicians should anticipate reduced availability of compounded GLP-1 products from outsourcing (503B) facilities and prioritize prescribing FDA-approved formulations when possible, especially as shortages have resolved.
FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, citing a lack of clinical need for outsourcing facilities to compound these drugs from bulk substances. If finalized, the rule could significantly limit large-scale compounding of popular GLP-1 agents, potentially affecting access, cost, and prescribing pathways for obesity and diabetes treatments.
The 503B bulks list identifies which active ingredients may be used by FDA-regulated outsourcing facilities to compound medications in bulk. In most cases, these facilities cannot legally compound drugs using bulk substances unless they appear on the list or the drug remains on the FDA’s shortage list.
After reviewing submitted nominations, the agency concluded there’s insufficient evidence of medical necessity to allow continued bulk compounding of these GLP-1 receptor agonists. The decision reflects improved supply of FDA-approved products and the agency’s position that compounding should be limited to specific clinical scenarios.
“When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need,” said FDA Commissioner Marty Makary, adding that the action is intended to “protect patients and preserve the integrity of the drug approval process.”
If finalized following public comment, the proposal would restrict large-scale compounding of these drugs—widely used for diabetes and obesity—unless they again appear on the FDA drug shortage list. The agency is now seeking public comment on the proposal through June 29, 2026, before issuing a final decision.